Tivic Health Systems Inc. has announced the receipt of two investigational new drug $(IND.AU)$ applications for their lead candidate, Entolimod™, from Statera Biopharma. These INDs are aimed at the treatment of acute radiation syndrome $(ARS.UK)$ and advanced cancers. The transfer of these applications facilitates Tivic's engagement with the FDA to advance Entolimod along its regulatory pathway. This development enables the pursuit of clinical trials addressing conditions such as neutropenia and lymphocyte exhaustion. Tivic's CEO, Jennifer Ernst, emphasized the company's immediate focus on Entolimod's application for acute radiation syndrome, while also exploring its potential anti-tumor effects in advanced cancer scenarios.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.